Advanced search
Publication Cover
OncoTargets and Therapy Volume 10, 2017 - Issue
Submit an article Journal homepage
185
Views
51
CrossRef citations to date
0
Altmetric
Review

nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors

Hatem H SolimanDepartment of Oncologic Sciences, Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL, USACorrespondence[email protected]
Pages 101-112 | Published online: 21 Dec 2016

Citations (51)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

José Pérez-García, Jesús Soberino, Fabricio Racca, María Gion, Agostina Stradella & Javier Cortés. (2020) Atezolizumab in the treatment of metastatic triple-negative breast cancer. Expert Opinion on Biological Therapy 20:9, pages 981-989.
Read now
Jodi A. Kagihara, Michelle Andress & Jennifer R. Diamond. (2020) Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions. Expert Review of Precision Medicine and Drug Development 5:2, pages 59-65.
Read now
Anne-Sophie Heimes & Marcus Schmidt. (2019) Atezolizumab for the treatment of triple-negative breast cancer. Expert Opinion on Investigational Drugs 28:1, pages 1-5.
Read now

Articles from other publishers (48)

Angela Flavia Serpico, Caterina Pisauro & Domenico Grieco. (2023) cGAS-dependent proinflammatory and immune homeostatic effects of the microtubule-targeting agent paclitaxel. Frontiers in Immunology 14.
Crossref
Anindita Dhara, Shourya Majumder, Srijoni Pahari & Debasish Kar. (2023) Improved Targeting of Therapeutics by Nanocarrier-Based Delivery in Cancer Immunotherapy and Their Future Perspectives. BioNanoScience 13:1, pages 278-299.
Crossref
Mohammad Darvishi, Foad Tosan, Pooria Nakhaei, Danial Amiri Manjili, Sahar Afzali Kharkouei, Ali Alizadeh, Saba Ilkhani, Farima Khalafi, Firoozeh Abolhasani Zadeh & Seyyed-Ghavam Shafagh. (2023) Recent progress in cancer immunotherapy: Overview of current status and challenges. Pathology - Research and Practice 241, pages 154241.
Crossref
Kedar Kirtane, Maie St. John, Harry Fuentes-Bayne, Sandip P. Patel, Armen Mardiros, Han Xu, Eric W. Ng, William Y. Go, Deborah J. Wong, John B. Sunwoo & John S. Welch. (2022) Genomic Immune Evasion: Diagnostic and Therapeutic Opportunities in Head and Neck Squamous Cell Carcinomas. Journal of Clinical Medicine 11:24, pages 7259.
Crossref
Elise Timon-David, Carla Perez & Anne Rodallec. (2022) Nanotherapeutics Plus Immunotherapy in Oncology: Who Brings What to the Table?. Pharmaceutics 14:11, pages 2326.
Crossref
Yiyu Xiao. (2022) Clinical studies of Atezolizumab contributing to FDA approvals. Highlights in Science, Engineering and Technology 8, pages 390-395.
Crossref
Jun Zhang, Zhijia Tang, Xi Guo, Yunxia Wang, Yuhong Zhou & Weimin Cai. (2022) Synergistic effects of nab-PTX and anti-PD-1 antibody combination against lung cancer by regulating the Pi3K/AKT pathway through the Serpinc1 gene. Frontiers in Oncology 12.
Crossref
Mohammad Zaki Ahmad, Ali S Alasiri, Mohammed Yahia Alasmary, MM Abdullah, Javed Ahmad, Basel A Abdel Wahab, Saif Aboud M Alqahtani, Kalyani Pathak, Gulam Mustafa, Mohammad Ahmad Khan, Riya Saikia & Urvashee Gogoi. (2022) Emerging advances in nanomedicine for breast cancer immunotherapy: opportunities and challenges. Immunotherapy 14:12, pages 957-983.
Crossref
Miriam Möller, Steffi Turzer, Georgi Ganchev, Andreas Wienke, Wolfgang Schütte, Barbara Seliger & Dagmar Riemann. (2022) Blood Immune Cell Biomarkers in Lung Cancer Patients Undergoing Treatment with a Combination of Chemotherapy and Immune Checkpoint Blockade. Cancers 14:15, pages 3690.
Crossref
Jing-jing Li, Jiu-hong Wang, Ya Dingv, Dan-dan Li, Xi-zhi Wen, Jing-jing Zhao, Hang Jiang, Xing Liu, Fu-xue Huang & Xiao-shi Zhang. (2021) Efficacy and safety of anti-PD-1 inhibitor combined with nab-paclitaxel in Chinese patients with refractory melanoma. Journal of Cancer Research and Clinical Oncology 148:5, pages 1159-1169.
Crossref
Ding-Li Yu, Zhi-Ping Lou, Feng-Yun Ma & Masoud Najafi. (2022) The interactions of paclitaxel with tumour microenvironment. International Immunopharmacology 105, pages 108555.
Crossref
Qu Liu, Guodong Zhao, Xiuping Zhang, Nan Jiang, Zhiming Zhao, Yang Wang, Shuai Xu, Lin Zhu, Wan Yee Lau, Guanghai Dai & Rong Liu. (2021) Nab-paclitaxel plus S-1 with or without PD-1 inhibitor in pancreatic ductal adenocarcinoma with only hepatic metastases: a retrospective cohort study. Langenbeck's Archives of Surgery 407:2, pages 633-643.
Crossref
Shelby A. Fertal, Johanna E. Poterala, Suzanne M. Ponik & Kari B. Wisinski. (2022) Stromal Characteristics and Impact on New Therapies for Metastatic Triple-Negative Breast Cancer. Cancers 14:5, pages 1238.
Crossref
Simone M. Goldinger, Kristina Buder-Bakhaya, Serigne N. Lo, Andrea Forschner, Meredith McKean, Lisa Zimmer, Chloe Khoo, Reinhard Dummer, Zeynep Eroglu, Elizabeth I. Buchbinder, Paolo A. Ascierto, Ralf Gutzmer, Elisa A. Rozeman, Christoph Hoeller, Douglas B. Johnson, Anja Gesierich, Peter Kölblinger, Naima Bennannoune, Justine V. Cohen, Katharina C. Kähler, Melissa A. Wilson, Jonathan Cebon, Victoria Atkinson, Jessica L. Smith, Olivier Michielin, Georgina V. Long, Jessica C. Hassel, Benjamin Weide, Lauren E. Haydu, Dirk Schadendorf, Grant McArthur, Patrick A. Ott, Christian Blank, Caroline Robert, Ryan Sullivan, Axel Hauschild, Matteo S. Carlino, Claus Garbe, Michael A. Davies & Alexander M. Menzies. (2022) Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. European Journal of Cancer 162, pages 22-33.
Crossref
Somayeh Vafaei, Angelina O. Zekiy, Ramadhan Ado Khanamir, Burhan Abdullah Zaman, Arman Ghayourvahdat, Hannaneh Azimizonuzi & Majid Zamani. (2022) Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier. Cancer Cell International 22:1.
Crossref
Lital Livni, Brooke A. Keating, Nathan T. Fiore, Justin G. Lees, David Goldstein & Gila Moalem-Taylor. (2022) Effects of combined chemotherapy and anti-programmed cell death protein 1 treatment on peripheral neuropathy and neuroinflammation in mice. Pain 163:1, pages 110-124.
Crossref
Ashleigh Hope, Samantha J. Wade, Morteza Aghmesheh & Kara L. Vine. (2022) Localized delivery of immunotherapy via implantable scaffolds for breast cancer treatment. Journal of Controlled Release 341, pages 399-413.
Crossref
Anvay Ukidve, Katharina Cu, Ninad Kumbhojkar, Joerg Lahann & Samir Mitragotri. (2021) Overcoming biological barriers to improve solid tumor immunotherapy. Drug Delivery and Translational Research 11:6, pages 2276-2301.
Crossref
Shelagh Verco, Holly Maulhardt, Michael Baltezor, Emily Williams, Marc Iacobucci, Alison Wendt, James Verco, Alyson Marin, Sam Campbell, Paul Dorman & Gere diZerega. (2020) Local administration of submicron particle paclitaxel to solid carcinomas induces direct cytotoxicity and immune-mediated tumoricidal effects without local or systemic toxicity: preclinical and clinical studies. Drug Delivery and Translational Research 11:5, pages 1806-1817.
Crossref
Ozge Gumusay, Chiara A. Wabl & Hope S. Rugo. (2021) Trials of Immunotherapy in Triple Negative Breast Cancer. Current Breast Cancer Reports 13:3, pages 171-185.
Crossref
Douglas Adkins, Jessica Ley, Omar Atiq, Steven Powell, William C. Spanos, Mark Gitau, Caron Rigden, Kevin Palka, Jingxia Liu & Peter Oppelt. (2021) Nanoparticle albumin-bound paclitaxel with cetuximab and carboplatin as first-line therapy for recurrent or metastatic head and neck cancer: A single-arm, multicenter, phase 2 trial. Oral Oncology 115, pages 105173.
Crossref
Peter Oppelt, Jessica Ley, Mackenzie Daly, Jason Rich, Randal Paniello, Ryan S. Jackson, Patrik Pipkorn, Jingxia Liu, Hiram Gay, Kevin Palka, Prakash Neupane, Steven Powell, William C. Spanos, Mark Gitau, Jose Zevallos, Wade Thorstad & Douglas Adkins. (2021) nab-Paclitaxel and cisplatin followed by cisplatin and radiation (Arm 1) and nab-paclitaxel followed by cetuximab and radiation (Arm 2) for locally advanced head and neck squamous-cell carcinoma: a multicenter, non-randomized phase 2 trial. Medical Oncology 38:4.
Crossref
Julia Foldi, Andrea Silber, Emily Reisenbichler, Kamaljeet Singh, Neal Fischbach, Justin Persico, Kerin Adelson, Anamika Katoch, Nina Horowitz, Donald Lannin, Anees Chagpar, Tristen Park, Michal Marczyk, Courtney Frederick, Trisha Burrello, Eiman Ibrahim, Tao Qing, Yalai Bai, Kim Blenman, David L. Rimm & Lajos Pusztai. (2021) Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer. npj Breast Cancer 7:1.
Crossref
Elizabeth A Mittendorf, Hong Zhang, Carlos H Barrios, Shigehira Saji, Kyung Hae Jung, Roberto Hegg, Andreas Koehler, Joohyuk Sohn, Hiroji Iwata, Melinda L Telli, Cristiano Ferrario, Kevin Punie, Frédérique Penault-Llorca, Shilpen Patel, Anh Nguyen Duc, Mario Liste-Hermoso, Vidya Maiya, Luciana Molinero, Stephen Y Chui & Nadia Harbeck. (2020) Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. The Lancet 396:10257, pages 1090-1100.
Crossref
Edson J. Comparetti, Paula M. P. Lins, João V. B. Quitiba & Valtencir Zucolotto. (2020) Cancer cell membrane-derived nanoparticles improve the activity of gemcitabine and paclitaxel on pancreatic cancer cells and coordinate immunoregulatory properties on professional antigen-presenting cells. Materials Advances 1:6, pages 1775-1787.
Crossref
Yang Shi. (2020) Clinical Translation of Nanomedicine and Biomaterials for Cancer Immunotherapy: Progress and Perspectives. Advanced Therapeutics 3:9.
Crossref
Evangelos Koustas, Panagiotis Sarantis, Athanasios G. Papavassiliou & Michalis V. Karamouzis. (2020) The Resistance Mechanisms of Checkpoint Inhibitors in Solid Tumors. Biomolecules 10:5, pages 666.
Crossref
John D. Martin, Horacio Cabral, Triantafyllos Stylianopoulos & Rakesh K. Jain. (2020) Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges. Nature Reviews Clinical Oncology 17:4, pages 251-266.
Crossref
Junxun Ma, Danyang Sun, Jinliang Wang, Chun Han, Yuanyu Qian, Guangying Chen, Xiaoyan Li, Juan Zhang, Pengfei Cui, Wushuang Du, Zhaozhen Wu, Shixue Chen, Xuan Zheng, Zhichao Yue, Jia Song, Chan Gao, Shangli Cai & Yi Hu. (2020) Immune checkpoint inhibitors combined with chemotherapy for the treatment of advanced pancreatic cancer patients. Cancer Immunology, Immunotherapy 69:3, pages 365-372.
Crossref
Hamdy A. Azim, Marwan Ghosn, Karima Oualla & Loay Kassem. (2019) Personalized treatment in metastatic triple‐negative breast cancer: The outlook in 2020. The Breast Journal 26:1, pages 69-80.
Crossref
Jindřich Kopeček & Jiyuan Yang. (2020) Polymer nanomedicines. Advanced Drug Delivery Reviews 156, pages 40-64.
Crossref
James VercoWilliam JohnstonMichael FrostMichael BaltezorPhilip J. Kuehl, Anita Lopez, Andrew Gigliotti, Steven A. Belinsky, Ronald WolffGere diZerega. (2019) Inhaled Submicron Particle Paclitaxel (NanoPac) Induces Tumor Regression and Immune Cell Infiltration in an Orthotopic Athymic Nude Rat Model of Non-Small Cell Lung Cancer. Journal of Aerosol Medicine and Pulmonary Drug Delivery 32:5, pages 266-277.
Crossref
Michael Untch, Christian Jackisch, Andreas Schneeweiss, Sabine Schmatloch, Bahriye Aktas, Carsten Denkert, Christian Schem, Hermann Wiebringhaus, Sherko Kümmel, Mathias Warm, Peter A. Fasching, Marianne Just, Claus Hanusch, John Hackmann, Jens-Uwe Blohmer, Kerstin Rhiem, Wolfgang D. Schmitt, Jenny Furlanetto, Bernd Gerber, Jens Huober, Valentina Nekljudova, Gunter von Minckwitz & Sibylle Loibl. (2019) NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69–GeparSepto. Journal of Clinical Oncology 37:25, pages 2226-2234.
Crossref
Javier Cortés, Fabrice André, Anthony Gonçalves, Sherko Kümmel, Miguel Martín, Peter Schmid, Florian Schuetz, Sandra M Swain, Valerie Easton, Erika Pollex, Regula Deurloo & Rebecca Dent. (2019) IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer. Future Oncology 15:17, pages 1951-1961.
Crossref
Cecilia RouxSoode Moghadas JafariRahul ShindeGordon DuncanDavid W. CesconJennifer SilvesterMandy F. ChuKelsey HodgsonThorsten BergerAndrew WakehamLuis PalomeroMar Garcia-ValeroMiguel A. PujanaTak W. MakTracy L. McGahaPaola Cappello & Chiara Gorrini. (2019) Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1. Proceedings of the National Academy of Sciences 116:10, pages 4326-4335.
Crossref
Albert A. De Vera, Pranav Gupta, Zining Lei, Dan Liao, Silpa Narayanan, Qiuxu Teng, Sandra E. Reznik & Zhe-Sheng Chen. (2019) Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo. Cancer Letters 442, pages 91-103.
Crossref
Peter SchmidSylvia AdamsHope S. RugoAndreas SchneeweissCarlos H. BarriosHiroji IwataVéronique DiérasRoberto HeggSeock-Ah ImGail Shaw WrightVolkmar HenschelLuciana MolineroStephen Y. ChuiRoel FunkeAmreen HusainEric P. WinerSherene LoiLeisha A. Emens. (2018) Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. New England Journal of Medicine 379:22, pages 2108-2121.
Crossref
Lironne Wein, Stephen J Luen, Peter Savas, Roberto Salgado & Sherene Loi. (2018) Checkpoint blockade in the treatment of breast cancer: current status and future directions. British Journal of Cancer 119:1, pages 4-11.
Crossref
Ammar Sukari, Misako Nagasaka & Nadine Abdallah. (2018) Responses in patients receiving sequential paclitaxel post progression on PD1 inhibitors. Oral Oncology 80, pages 100-102.
Crossref
Mark Stroh. (2017) Designing In and Around Tolerability Considerations for Immunotherapy Combinations. Clinical Pharmacology & Therapeutics 103:4, pages 558-561.
Crossref
Mark R. Nathan & Peter Schmid. (2018) The emerging world of breast cancer immunotherapy. The Breast 37, pages 200-206.
Crossref
Ana Seca & Diana Pinto. (2018) Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application. International Journal of Molecular Sciences 19:1, pages 263.
Crossref
小萌 徐. (2018) New Progress in Breast Cancer Immunotherapy. Advances in Clinical Medicine 08:01, pages 47-52.
Crossref
Michele Graciotti, Cristiana Berti, Harm-Anton Klok & Lana Kandalaft. (2017) The era of bioengineering: how will this affect the next generation of cancer immunotherapy?. Journal of Translational Medicine 15:1.
Crossref
Gloria Mittica, Eleonora Ghisoni, Gaia Giannone, Massimo Aglietta, Sofia Genta & Giorgio Valabrega. (2017) Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity. Oncotarget 8:52, pages 90532-90544.
Crossref
Zishuo I. Hu, Alice Y. Ho & Heather L. McArthur. (2017) Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer. International Journal of Radiation Oncology*Biology*Physics 99:1, pages 153-164.
Crossref
Paul Zolkind & Ravindra Uppaluri. (2017) Checkpoint immunotherapy in head and neck cancers. Cancer and Metastasis Reviews 36:3, pages 475-489.
Crossref
Diana Cláudia Gouveia Alves Pinto, Ana Maria Loureiro Seca & Artur Manuel Soares Silva. 2017. Anticancer Plants: Clinical Trials and Nanotechnology. Anticancer Plants: Clinical Trials and Nanotechnology 105 151 .

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.